Monoclonal antibody shows promise in slowing progression of ALS

New research reveals a type of monoclonal antibody already tested in certain forms of cancer may be a promising treatment in stopping the progression of amyotrophic lateral sclerosis, or ALS, a fatal neurodegenerative disease.

Related Keywords

Oregon ,United States ,Lawrence Steinman ,Randall Woltjer ,Shanuf Roemer ,Katie Emberley ,Lisa Ryner ,Michael Leviten ,Alina Bogachuk ,Lily Ramsey ,Audie Chiot ,Gissellea Jimenez ,Dillon Brownell ,Bahareh Ajami ,Dennis Dickson ,School Of Medicine ,Proceedings Of The National Academy Sciences ,Stanford University ,Oregon Health Science University ,Drug Administration ,Oregon Health ,Science University ,National Academy ,Mayo Clinic ,Pasithea Therapeutics ,Immunotherapy ,Amyotrophic Lateral Sclerosis ,Ntibody ,Rain ,Dancer ,High Throughput Screening ,Immune System ,Mmunology ,Icrobiology ,Monoclonal Antibody ,Ouse Model ,Multiple Sclerosis ,Eurodegenerative Disease ,Neuroscience ,Mh ,Protein ,Research ,Clerosis ,